Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Asthma
Interventions: Flovent Diskus® 100 mcg, Flovent Diskus® 250 mcg, Flovent Diskus® 500 mcg, Advair Diskus® 100/50 mcg, Advair Diskus® 250/50 mcg; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 5 Years and older
Enrollment: 574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 28
States / cities: Tucson, Arizona • Oakland, California • San Francisco, California + 16 more

Conditions: Healthy Participants
Interventions: Immunoglobulin G; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Conditions: Healthy
Interventions: clopidogrel, placebo, omeprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Hypermobile Ehlers-Danlos Syndrome, Pain Assessment
Interventions: Oxytocin, Placebo; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Visual Acuity
Interventions: TEST Contact Lens, CONTROL Contact Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 283 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 13
States / cities: Montgomery, Alabama • Jacksonville, Florida • Sarasota, Florida + 10 more

Conditions: Breast Cancer Female
Interventions: Supine MRI; Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Healthy
Interventions: Dabigatran etexilate (DE), Rosuvastatin, PF-07081532; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Prostate Carcinoma
Interventions: Dixon MRI, Magnetic Resonance Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV
Interventions: CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), ACU-026-001-1 (labeled as empty LNP); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee

Conditions: Visual Acuity
Interventions: Spectacles, ACUVUE OASYS®1-Day with HydraLuxe™ Technology; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 42 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 3
States / cities: Jacksonville, Florida • Longwood, Florida • New York, New York

Conditions: Healthy
Interventions: Emotion valence, Time, TMS Stimulation; Other · Device
Lead sponsor: University of California, Santa Barbara; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Leukapheresis, Dendritic Cell (DC) Vaccine; Procedure · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Phantom Limb Pain
Interventions: direct observation, mental visualization; Behavioral
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Interference With Routine Analytical Tests, Stability of in Vitro Diagnostic Reagents, Illicit Drug Use
Interventions: Device storage condition, Interferent application; Device
Lead sponsor: Intelligent Bio Solutions Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Sclerosing Adenosis
Interventions: Follow-Up, Physical Examination, Questionnaire Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: COVID 19
Interventions: HLX71, Placebo; Drug · Other
Lead sponsor: Hengenix Biotech Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Healthy
Interventions: Palbociclib Formulation Reference, Palbociclib Formulation Test; Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections
Interventions: Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infection
Interventions: PENNVAX-B, GENEVAX IL-12-4532, PLACEBO, IL-15 adjuvant; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Melanoma, BRAF V600 Mutation Positive
Interventions: Itraconazole, Rifampin, Vemurafenib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteer
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy, Drug Drug Interaction
Interventions: Itraconazole, Rifampin, KBP-5074; Drug
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Systemic Scleroderma
Interventions: Spatial-frequency domain imaging (SFDI); Other
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteer
Interventions: GDC-0941; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Best African American Response to Asthma Drugs

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

Oxytocin for Hypermobile Ehlers-Danlos Syndrome

Clinical Evaluation of Two Approved Contact Lenses

21DIF039: Prone to Supine Breast MRI II, P2S2 Breast MRI Trial

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

Ocular Characteristics in Contact Lens and Spectacle Wear

LPFC Organization in Emotion-Duration Difference Estimation

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

Study to Assess the Efficacy of Direct Observation and Mental Visualization of Foot Movements to Treat Bilateral Lower Limb Phantom Limb Pain

Interference and Stability Evaluation of the Intelligent Fingerprinting Drug Screening System

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects

A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

Longitudinal Spatial Frequency Domain Imaging Study

A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers